AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34724251 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat 2.5 mg/kg
Number of subjects: 24
Study 34724251 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat 1.5 mg/kg and 2.0 mg/kg
Number of subjects: 24
Study 34724251 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat (all doses)
Number of subjects: 24
Study 33236115 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 5 mg
Number of subjects: 316
Study 33236115 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 10 mg
Number of subjects: 316
Study 33236115 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 15 mg
Number of subjects: 316
Study 33236115 — intervention group
Group type: COMPARATOR
Intervention: Dulaglutide 1.5 mg
Number of subjects: 316
Study 33236115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 316
Study 32651711 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-surgeon bilateral TKA
Number of subjects: 246
Study 32651711 — intervention group
Group type: COMPARATOR
Intervention: Single-surgeon bilateral TKA
Number of subjects: 246
Study 34198554 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT + IF
Number of subjects: 14
Study 32544082 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel-aspirin therapy
Number of subjects: 3044
Study 34673532 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging smoking cessation intervention
Number of subjects: 535
Study 34673532 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 535
Study 35112550 — intervention group
Group type: EXPERIMENTAL
Intervention: New treatment
Number of subjects: 0
Study 35112550 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 32780744 — intervention group
Group type: EXPERIMENTAL
Intervention: ADL-IADL-HELP-20
Number of subjects: 1506
Study 32780744 — intervention group
Group type: COMPARATOR
Intervention: ADL-IADL-DIFFICULTY-20
Number of subjects: 1506
Study 32780744 — intervention group
Group type: EXPERIMENTAL
Intervention: ADL-IADL-DIFFICULTY-9
Number of subjects: 1506
Study 34582903 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (1.5 mg/kg bolus followed by 0.1 mg/kg/min infusion)
Number of subjects: 69
Study 34582903 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 69
Study 34582903 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (1.5 mg/kg bolus followed by 1.5 mg/kg/h infusion)
Number of subjects: 69
Study 37821181 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided PCI
Number of subjects: 443
Study 37821181 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR-guided PCI
Number of subjects: 443
Study 37821181 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-IRA PCI despite QFR >0.80
Number of subjects: 443
Study 37821181 — intervention group
Group type: COMPARATOR
Intervention: Deferred PCI for non-IRA lesions
Number of subjects: 443
Study 33687025 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine + Itraconazole
Number of subjects: 152
Study 33687025 — intervention group
Group type: COMPARATOR
Intervention: Terbinafine
Number of subjects: 152
Study 33687025 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole
Number of subjects: 152
Study 32711541 — intervention group
Group type: EXPERIMENTAL
Intervention: β‐alanine supplementation (4.8 g/day for 6 weeks)
Number of subjects: 13
Study 32711541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 32711541 — intervention group
Group type: EXPERIMENTAL
Intervention: β‐alanine supplementation
Number of subjects: 13
Study 35675708 — intervention group
Group type: EXPERIMENTAL
Intervention: Pay-it-forward intervention (participants receive free gonorrhea/chlamydia testing as gifts)
Number of subjects: 301
Study 35675708 — intervention group
Group type: EXPERIMENTAL
Intervention: Pay-it-forward intervention
Number of subjects: 301
Study 35675708 — intervention group
Group type: COMPARATOR
Intervention: Pay-what-you-want
Number of subjects: 301
Study 35675708 — intervention group
Group type: COMPARATOR
Intervention: Standard payment
Number of subjects: 301
Study 33422558 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% atropine
Number of subjects: 350
Study 33422558 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025% atropine
Number of subjects: 350
Study 33422558 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% atropine
Number of subjects: 350
Study 33422558 — intervention group
Group type: COMPARATOR
Intervention: Placebo (switched to 0.05% atropine in the second year)
Number of subjects: 350
Study 33422558 — intervention group
Group type: EXPERIMENTAL
Intervention: All concentrations of atropine
Number of subjects: 350
Study 35257058 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose roxadustat (∼1–1.4 mg/kg)
Number of subjects: 100
Study 35257058 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose roxadustat (∼1.5–2 mg/kg)
Number of subjects: 100
Study 32639099 — intervention group
Group type: EXPERIMENTAL
Intervention: ASC-enriched fat grafts (≥20 × 106 viable ex vivo‐expanded ASCs per milliliter fat)
Number of subjects: 0
Study 32639099 — intervention group
Group type: COMPARATOR
Intervention: Conventional nonenriched fat grafts
Number of subjects: 0
Study 32639099 — intervention group
Group type: EXPERIMENTAL
Intervention: ASC-enriched fat grafts
Number of subjects: 0
Study 35553816 — intervention group
Group type: EXPERIMENTAL
Intervention: Dox (5 mg/kg/week)
Number of subjects: 10
Study 35553816 — intervention group
Group type: EXPERIMENTAL
Intervention: Es-Exos (50 ug/animal/twice a week)
Number of subjects: 10
Study 35553816 — intervention group
Group type: EXPERIMENTAL
Intervention: Dox+Es-Exos
Number of subjects: 10
Study 35553816 — intervention group
Group type: COMPARATOR
Intervention: Saline (Con)
Number of subjects: 10
Study 35553816 — intervention group
Group type: EXPERIMENTAL
Intervention: MEF-Exos (50 ug/animal/twice a week)
Number of subjects: 10
Study 32555091 — intervention group
Group type: EXPERIMENTAL
Intervention: Italian version of the Foot‐and‐Ankle‐Disability‐Index (FADI) questionnaire
Number of subjects: 60
Study 32555091 — intervention group
Group type: EXPERIMENTAL
Intervention: FADI questionnaire
Number of subjects: 60
Study 34789840 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue-green light (478/490/497 nm)
Number of subjects: 3
Study 34789840 — intervention group
Group type: COMPARATOR
Intervention: Blue light (459/452/459 nm)
Number of subjects: 3
Study 34961542 — intervention group
Group type: EXPERIMENTAL
Intervention: New regression formula (SSD, AL, SSW)
Number of subjects: 121
Study 34961542 — intervention group
Group type: COMPARATOR
Intervention: Holladay 1
Number of subjects: 121
Study 34961542 — intervention group
Group type: COMPARATOR
Intervention: SRK/T
Number of subjects: 121
Study 34961542 — intervention group
Group type: COMPARATOR
Intervention: Haigis
Number of subjects: 121
Study 35064786 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5D SSD model
Number of subjects: 127
Study 35064786 — intervention group
Group type: COMPARATOR
Intervention: 2D model
Number of subjects: 127
Study 33069281 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 μg vaccine
Number of subjects: 640
Study 33069281 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 μg vaccine
Number of subjects: 640
Study 33069281 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 μg vaccine
Number of subjects: 640
Study 33069281 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 μg vaccine on day 0
Number of subjects: 640
Study 33069281 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 μg vaccine on days 0 and 14
Number of subjects: 640
Study 33069281 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 μg vaccine on days 0 and 21
Number of subjects: 640
Study 33069281 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 μg vaccine on days 0 and 28
Number of subjects: 640
Study 33069281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 640
Study 35608490 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear implantation virtual reality simulation training
Number of subjects: 18
Study 35608490 — intervention group
Group type: COMPARATOR
Intervention: Mastoidectomy virtual reality simulation training alone
Number of subjects: 18
Study 32243316 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced cough during colposcopy-guided cervical biopsy
Number of subjects: 110
Study 32243316 — intervention group
Group type: COMPARATOR
Intervention: No cough during colposcopy-guided cervical biopsy
Number of subjects: 110
Study 35922472 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight reduction intervention
Number of subjects: 195
Study 35922472 — intervention group
Group type: COMPARATOR
Intervention: Control group (no weight reduction intervention)
Number of subjects: 195
Study 33356421 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoropyrimidine (FP) plus oxaliplatin
Number of subjects: 5457
Study 33252543 — intervention group
Group type: EXPERIMENTAL
Intervention: Photopic luminance
Number of subjects: 5
Study 33252543 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesopic luminance
Number of subjects: 5
Study 33252543 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral contour interaction (Mesopic)
Number of subjects: 5
Study 33252543 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral contour interaction (Photopic)
Number of subjects: 5
Study 33252543 — intervention group
Group type: COMPARATOR
Intervention: Foveal contour interaction
Number of subjects: 5
Study 33252543 — intervention group
Group type: COMPARATOR
Intervention: Peripheral contour interaction
Number of subjects: 5
Study 34914037 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol levels in brain and subcutaneous adipose tissue measured through microdialysis.
Number of subjects: 48
Study 34914037 — intervention group
Group type: COMPARATOR
Intervention: Computed tomography Rotterdam score
Number of subjects: 48
Study 34914037 — intervention group
Group type: EXPERIMENTAL
Intervention: Biochemical biomarkers S-100B and neuron-specific enolase (NSE)
Number of subjects: 48
Study 34914037 — intervention group
Group type: COMPARATOR
Intervention: Injury Severity Score (ISS) and Acute Physiology and Chronic Health Evaluation Score (APACHE II)
Number of subjects: 48
Study 34607175 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 valerate
Number of subjects: 32
Study 34607175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 35249510 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC)
Number of subjects: 24
Study 35249510 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Plac)
Number of subjects: 24
Study 32919015 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RET)
Number of subjects: 30
Study 34719872 — intervention group
Group type: EXPERIMENTAL
Intervention: guselkumab 100 mg every 4 weeks
Number of subjects: 739
Study 34719872 — intervention group
Group type: EXPERIMENTAL
Intervention: guselkumab 100 mg at weeks 0 and 4 and then every 8 weeks
Number of subjects: 739
Study 34719872 — intervention group
Group type: COMPARATOR
Intervention: guselkumab (placebo group crossover to guselkumab 100 mg every 4 weeks at week 24)
Number of subjects: 739
Study 34776002 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamins A, B, C, D, and E supplementation (25,000 IU daily of A, 600,000 IU once of D, 300 IU twice daily of E, 500 mg four times daily of C, one amp daily of B complex for 7 days)
Number of subjects: 60
Study 34776002 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vitamins or placebo)
Number of subjects: 60
Study 34929196 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention to support caregivers (details not specified)
Number of subjects: 125
Study 34929196 — intervention group
Group type: EXPERIMENTAL
Intervention: Resources, strategies, and practices perceived as helpful (details not specified)
Number of subjects: 125
Study 34929196 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination and testing protocols (details not specified)
Number of subjects: 125
Study 34929196 — intervention group
Group type: EXPERIMENTAL
Intervention: Supports for bereaved caregivers (details not specified)
Number of subjects: 125
Study 34291527 — intervention group
Group type: EXPERIMENTAL
Intervention: Game training (50 min, three times per week for 8 weeks)
Number of subjects: 72
Study 34291527 — intervention group
Group type: COMPARATOR
Intervention: Regular nursing care
Number of subjects: 72
Study 32367188 — intervention group
Group type: EXPERIMENTAL
Intervention: cQFR (contrast-flow quantitative flow ratio)
Number of subjects: 87
Study 32367188 — intervention group
Group type: EXPERIMENTAL
Intervention: cQFR
Number of subjects: 87
Study 32367188 — intervention group
Group type: EXPERIMENTAL
Intervention: Diameter stenoses (DS) and area stenoses (AS) in vessels with positive stress MRI
Number of subjects: 87
Study 34973154 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (6 g/day for 3 months)
Number of subjects: 51
Study 34973154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 34393125 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser disinfection
Number of subjects: 60
Study 34393125 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic activated irrigation with 2.5% NaOCl
Number of subjects: 60
Study 34393125 — intervention group
Group type: COMPARATOR
Intervention: Conventional irrigation with 2.5% NaOCl
Number of subjects: 60
Study 35675606 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin 2% gel
Number of subjects: 307
Study 35675606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 307
Study 33216421 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin (500 mg/day)
Number of subjects: 88
Study 33216421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 34369402 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction (S+) during EBUS‐TBNA
Number of subjects: 59
Study 34369402 — intervention group
Group type: COMPARATOR
Intervention: No suction (S-) during EBUS‐TBNA
Number of subjects: 59
Study 34551584 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumateperone 42 mg/day
Number of subjects: 377
Study 34551584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 377
Study 36154666 — intervention group
Group type: EXPERIMENTAL
Intervention: Throat spray with selected Lactobacilli (verum group, n=41)
Number of subjects: 78
Study 36154666 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group, n=37)
Number of subjects: 78
Study 33631360 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 288
Study 33631360 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Regulation (SR)
Number of subjects: 288
Study 34004447 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory updating training using neutral stimuli
Number of subjects: 124
Study 34004447 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory updating training using negative stimuli
Number of subjects: 124
Study 34004447 — intervention group
Group type: COMPARATOR
Intervention: Non-adaptive working memory updating training
Number of subjects: 124
Study 32302659 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran-based prime
Number of subjects: 80
Study 32302659 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid prime
Number of subjects: 80
Study 33819474 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 1843
Study 33819474 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 1843
Study 32014057 — intervention group
Group type: EXPERIMENTAL
Intervention: Aim2Be app with health coaching
Number of subjects: 200
Study 32014057 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (no access to health coaching)
Number of subjects: 200
Study 32580841 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone hydrochloride 0.1mg/kg intravenous injection 10 mins before anesthesia induction
Number of subjects: 60
Study 32580841 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 10 ml intravenous injection
Number of subjects: 60
Study 33321380 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise training (RET) for 8 weeks
Number of subjects: 44
Study 33321380 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 44
Study 35562327 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib (250 mg) + Docetaxel (60 mg/m) or Pemetrexed (500 mg/m)
Number of subjects: 22
Study 35562327 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (60 mg/m) or Pemetrexed (500 mg/m) without gefitinib
Number of subjects: 22
Study 34271122 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciliary neurotrophic factor (CNTF)
Number of subjects: 42
Study 34271122 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin (IL-17)
Number of subjects: 42
Study 34271122 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-γ-inducible protein 10 (IP-10)
Number of subjects: 42
Study 34271122 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatocyte growth factor (HGF)
Number of subjects: 42
Study 34387527 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser therapy plus 4% hydroquinone (HQ)
Number of subjects: 31
Study 34387527 — intervention group
Group type: COMPARATOR
Intervention: Intraderal tranexamic acid (TA) plus 4% hydroquinone (HQ)
Number of subjects: 31
Study 35254433 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support (CDS) system
Number of subjects: 8937
Study 35254433 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CDS system)
Number of subjects: 8937
Study 32241260 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated home-environmental intervention package and early child development programme
Number of subjects: 317
Study 32241260 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor kitchen air quality measurements
Number of subjects: 317
Study 35944061 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose azithromycin
Number of subjects: 0
Study 35944061 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34444403 — intervention group
Group type: EXPERIMENTAL
Intervention: TRT + Parenting (TRT + P)
Number of subjects: 119
Study 34444403 — intervention group
Group type: COMPARATOR
Intervention: TRT
Number of subjects: 119
Study 34444403 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 119
Study 32498620 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavacamten, once-daily oral administration for 30 weeks
Number of subjects: 0
Study 32498620 — intervention group
Group type: COMPARATOR
Intervention: Placebo, matching placebo for 30 weeks
Number of subjects: 0
Study 32498620 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavacamten
Number of subjects: 0
Study 32498620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35790955 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin sealant (etch-and-rinse + Conceal F)
Number of subjects: 39
Study 35790955 — intervention group
Group type: COMPARATOR
Intervention: Giomer sealant (self-etch primer + BeautiSealant)
Number of subjects: 39
Study 35790955 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional resin sealants
Number of subjects: 39
Study 35790955 — intervention group
Group type: COMPARATOR
Intervention: Giomer sealants
Number of subjects: 39
Study 33674221 — intervention group
Group type: EXPERIMENTAL
Intervention: Education intervention
Number of subjects: 78
Study 33674221 — intervention group
Group type: COMPARATOR
Intervention: Control group (no education)
Number of subjects: 78
Study 32854972 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 1000
Study 32854972 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 1000
Study 35213351 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided hydrodilatation of glenohumeral joint combined with acupotomy
Number of subjects: 63
Study 35213351 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided hydrodilatation of glenohumeral joint
Number of subjects: 63
Study 34127029 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise and health behaviour support
Number of subjects: 264
Study 34127029 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise and no health behaviour support
Number of subjects: 264
Study 34127029 — intervention group
Group type: COMPARATOR
Intervention: Stretching-toning and health behaviour support
Number of subjects: 264
Study 34127029 — intervention group
Group type: COMPARATOR
Intervention: Stretching-toning and no health behaviour support
Number of subjects: 264
Study 32778531 — intervention group
Group type: EXPERIMENTAL
Intervention: Driver's Risk Field (DRF) assessment using 77 positions of obstacles in a driving simulator
Number of subjects: 8
Study 35139105 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 600mg followed by misoprostol
Number of subjects: 351
Study 35139105 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by misoprostol
Number of subjects: 351
Study 35139105 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone followed by misoprostol
Number of subjects: 351
Study 34181449 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedside presentation group (n = 476)
Number of subjects: 919
Study 34181449 — intervention group
Group type: COMPARATOR
Intervention: Outside the room presentation group (n = 443)
Number of subjects: 919
Study 36480545 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunisation health education intervention based on Social Cognitive Theory, delivered through five health education sessions.
Number of subjects: 392
Study 36480545 — intervention group
Group type: COMPARATOR
Intervention: Usual care (standard care)
Number of subjects: 392
Study 36480545 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunisation health education intervention
Number of subjects: 392
Study 33270229 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror Therapy (MT)
Number of subjects: 26
Study 33270229 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mirror therapy)
Number of subjects: 26
Study 35228490 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D 200,000 IU (single dose)
Number of subjects: 40
Study 35228490 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study 34128838 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg twice a day for 14 days
Number of subjects: 30